EHA 2021 | CC-220-MM-001: IberDd, IberVd and IbrKd for R/R myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, gives an overview of the findings of the Phase I/II CC-220-MM-001 trial (NCT02773030) exploring iberdomide plus daratumumab plus dexamethasone (IberDd), iberdomide plus bortezomib plus dexamethasone (IberVd) and iberdomide plus carfilzomib plus dexamethasone (IberKd) for patients with relapsed/refractory (R/R) multiple myeloma. Prof. Lonial reports that IberDd has a response rate of around 45%, IberVd has a response rate of around 56% and IberKd has a response rate of around 50%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
You know, we’re very excited about iberdomide, which is the agent formerly known as CC-220. And in the initial Phase I study, we reported that the activity of iberdomide plus dexamethasone in part of the Phase I study had a response rate of about 30% in mostly triple-class refractory patients.
More recently, what we’re reporting at EHA is the cohorts E, F, and G, which are combinations of iberdomide with dara, iberdomide with bortezomib, or iberdomide with carfilzomib...
You know, we’re very excited about iberdomide, which is the agent formerly known as CC-220. And in the initial Phase I study, we reported that the activity of iberdomide plus dexamethasone in part of the Phase I study had a response rate of about 30% in mostly triple-class refractory patients.
More recently, what we’re reporting at EHA is the cohorts E, F, and G, which are combinations of iberdomide with dara, iberdomide with bortezomib, or iberdomide with carfilzomib. And what we know about these three combinations is that the iber plus dara cohort has a response rate of about 45%, the iber plus bortezomib cohort has a response rate of about 56%, and the iber plus carfilzomib combination has a response rate of about 50% as well.
And what I think we’re excited about, obviously, is that iberdomide can be combined at full dose with each of these commonly used agents, that the safety profile, there’s nothing new that’s jumping up in terms of adverse events, particularly as part of the combination. And more importantly, that these are really setting the ground for subsequent Phase II and Phase III trials that will lead to what we hope will be the eventual FDA approval of iberdomide in combination with many of these effective therapies.
Read more...
